*Press Release*

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

# Lupin appoints Dr. Kamal K. Sharma as Advisor to the Company

**Mumbai, Baltimore, September 17, 2018**: Lupin Limited announced today the appointment of Dr. Kamal K. Sharma as Advisor to the company, for a period of one year effective October 1, 2018.

During this period, Dr. Sharma will continue to hold the position of Vice Chairman of the Board in a Non-Executive capacity. Dr. Sharma has vast industry experience spanning over four decades and has held a range of senior management positions in the fields of projects, operations, corporate development and general management in the pharmaceutical and chemical industry.

Commenting on the appointment, **Ms. Vinita Gupta, Chief Executive Officer** and **Mr. Nilesh Gupta, Managing Director** stated, "Dr. Sharma has served Lupin for over 30 years and has helped drive the company to be a formidable pharmaceutical player globally. His decades of experience in the global pharmaceutical industry and commitment to our success has proved invaluable to the company. Dr. Sharma has always embodied the values that we believe in at Lupin. We look forward to his continued guidance on our strategic choices as we accelerate our efforts to evolve and grow our business."

Speaking on the matter, **Dr. Kamal K. Sharma, Vice-Chairman**, said, "I am honored by the confidence placed in me by the board, and look forward to the opportunity to guide Lupin through the dynamic changes in the global pharmaceutical industry."

**About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8$^{th}$ largest generics pharmaceutical company both in terms of market capitalization (30$^{th}$ June 2018, Bloomberg) and revenues (31$^{st}$ March 2018, Bloomberg LTM) globally. The Company is the 4$^{th}$ largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3$^{rd}$ largest Indian pharmaceutical company by global revenues (31$^{st}$ March 2018, Bloomberg LTM); 6$^{th}$ largest generic pharmaceutical player in Japan and 5$^{th}$ largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31$^{st}$ March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter –www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

***Press Release***

| BSE: 500257 | NSE: LUPIN | REUTERS: LUPIN.BO | BLOOMBERG: LPC IN |
|---|---|---|---|

**For further information or queries, please contact –**

**Pooja Thakran**
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

**Arvind Bothra**
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66402137

**Safe Harbor Statement*